Platinum-Based Therapeutics for Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1323
Special Issue Editors
Interests: chemoresistance; cancer metabolism; chemosensitizers; cisplatin; mitochondria; molecular pharmacology; antioxidants; inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Despite the recent clinical introduction of immunotherapy [1], platinum-based agents, such as cisplatin, carboplatin, and oxaliplatin, still remain the most used drugs in chemotherapy for the treatment of solid tumors. In addition to the severe toxicity of platinum-based drugs, such as nephrotoxicity, ototoxicity, and peripheral neurotoxicity, the onset of drug resistance represents one of the main issues related to their clinical use [2]. In light of these considerations, there is still the need to keep investigating this field.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Deepening the current knowledge about platinum-based therapeutics’ implications in cancer;
- Investigating the molecular mechanisms involved in platinum-based agents cancer resistance and the possible emerging strategies to overcome it (thus, we encourage new research articles related to monotherapy or combined approaches, as well as the application of drug delivery systems);
- Untangling the role of the tumor microenvironment (TME) in the onset of platinum agents’ resistance;
- Investigating if gender difference is involved in patients’ response to treatment.
We look forward to receiving your contributions.
Dr. Monica Montopoli
Dr. Veronica Cocetta
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- platinum agents
- cisplatin
- carboplatin
- oxaliplatin
- cancer metabolism
- tumor microenvironment
- drug resistance
- drug delivery
- gender medicine
